Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.23.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (9,930) $ (13,771)
Stock option compensation to employees and directors 4,422 6,000
Stock options and warrants issued to consultants 221 655
Common stock issued to consultants 92 97
Amortization of operating lease right-of-use asset 46 42
Change in operating assets and liabilities:    
Receivables (224) (29)
Prepaid expenses and other current assets (775) (208)
Accounts payable (59) 129
Accrued expenses 44 631
Operating lease liability (46) (38)
Net cash used in operating activities (6,209) (6,492)
Cash flows from investing activities:    
Disbursements to acquire short-term investments (44,411) (22,486)
Proceeds from maturities of short-term investments 38,809 11,758
Net cash used in investing activities (5,602) (10,728)
Cash flows from financing activities:    
Proceeds from sale of common stock pursuant to employee stock purchase plan 13 13
Proceeds from exercise of stock options and warrants 353 439
Net cash provided by financing activities 366 452
Net decrease in cash and cash equivalents (11,445) (16,768)
Cash and cash equivalents at beginning of year 12,360 29,128
Cash and cash equivalents at end of year 915 12,360
Supplemental cash flow information:    
Cash proceeds from interest income $ 838 $ 23